Evidence map›Paper›PMID 35424384›Full record

ArticleRSC advances2021

CS/Au/MWCNT nanohybrid as an efficient carrier for the sustained release of 5-FU and a study of its cytotoxicity on MCF-7.

E A K Nivethaa, S Dhanavel, V Narayanan, S Narayana Kalkura, J Sivasankari, N Sivanandham, A Stephen

Open access · goldAbstract read
In one paragraph

Article in RSC advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Bridging solubility, stability, and translation: advances in carbon nanotube-based drug delivery systems.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026
    Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

E A K NivethaaDepartment of Physics, Anna University Guindy Chennai-25 India.
S DhanavelMaterials Chemistry & Metal Fuel Cycle Group, Indira Gandhi Centre for Atomic Research Kalpakkam India.
V NarayananDepartment of Inorganic Chemistry, University of Madras Guindy Campus Chennai 600 025 India.ORCID https://orcid.org/0000-0003-0653-8170
S Narayana KalkuraCrystal Growth Centre, Anna University Guindy Chennai-25 India.ORCID https://orcid.org/0000-0001-5777-2907
J SivasankariDepartment of Physics, Anna University Guindy Chennai-25 India.
N SivanandhamDepartment of Physics, Anna University Guindy Chennai-25 India.
A StephenDepartment of Nuclear Physics, University of Madras Guindy Campus Chennai-25 India stephen_arum@hotmail.com stephen@unom.ac.in +044-22351269 +044-22202802.ORCID https://orcid.org/0000-0003-2434-672X
University of Madras · INAnna University, Chennai · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The chemical reduction method has been used to adeptly synthesize a CS/Au/MWCNT nanocomposite, to be used as a carrier for the effectual delivery of the anticancer drug 5-Fluorouracil. The work aims at utilizing the less investigated ternary nanocomposite system containing chitosan (CS), gold (Au) and MWCNT's to attain higher encapsulation efficiency and to enable a more sustained and prolonged release of 5-FU. This system has improved cytotoxicity when compared to the CS/Au binary system. The prepared sample has been characterized using various techniques that confirm the formation of the nanocomposite, encapsulation of 5-FU into the nanocomposite, the structure of 5-FU and Au in the nanocomposite and the formation of the polymer matrix nanocomposite. An increase in the encapsulation efficiency to 98% and loading efficiency to 43% is observed when compared to the binary composite, elucidating the importance of incorporation of carbon nanotubes into the nanocomposite. A reduction in the release percentage of 5-FU by 40% indicates a more prolonged release, which will enable a reduction of the number of dosages that need to be administered. This in turn leads to a reduction in the side effects posed by the drug 5-FU. Moreover, the effectiveness of the drug loaded nanocomposite system towards the inhibition of breast cancer cells, apparent from the attainment of 50% cell viability while taking sample concentrations as low as 25 μg ml

Identifiers

PMID35424384
PMCPMC8694463
OpenAlexW3124198318

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.